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Background: Asthma, one of the most common chronic respiratory diseases, affects about 3 million Canadians. The
objective of this study is to provide a comprehensive evaluation of the published literature that reports on the
clinical, economic, and humanistic burden of asthma in Canada.
Methods: A search of the PubMed, EMBASE, and EMCare databases was conducted to identify original research
published between 2000 and 2011 on the burden of asthma in Canada. Controlled vocabulary with “asthma” as the
main search concept was used. Searches were limited to articles written in English, involving human subjects and
restricted to Canada. Articles were selected for inclusion based on predefined criteria like appropriate study design,
disease state, and outcome measures. Key data elements, including year and type of research, number of study
subjects, characteristics of study population, outcomes evaluated, results, and overall conclusions of the study, were
abstracted and tabulated.
Results: Thirty-three of the 570 articles identified by the clinical and economic burden literature searches and 14 of
the 309 articles identified by the humanistic burden literature searches met the requirements for inclusion in this
review. The included studies highlighted the significant clinical burden of asthma and show high rates of
healthcare resource utilization among asthma patients (hospitalizations, ED, physician visits, and prescription
medication use). The economic burden is also high, with direct costs ranging from an average annual cost of $366
to $647 per patient and a total annual population-level cost ranging from ~ $46 million in British Columbia to ~
$141 million in Ontario. Indirect costs due to time loss from work, productivity loss, and functional impairment
increase the overall burden. Although there is limited research on the humanistic burden of asthma, studies show
a high (31%-50%) prevalence of psychological distress and diminished QoL among asthma patients relative to
subjects without asthma.
Conclusions: As new therapies for asthma become available, economic evaluations and assessment of clinical and
humanistic burden will become increasingly important. This report provides a comprehensive resource for health
technology assessment that will assist decision making on asthma treatment selection and management guidelines
in Canada.
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Asthma, an inflammatory disorder of the airways [1], ac-
counts for roughly 80% of cases of chronic respiratory
disease in Canada [2]. It affects more than 3 million
Canadians and roughly 235 million people worldwide
[3,4]. According to Statistics Canada, 8.5% of the popula-
tion aged 12 and older has been diagnosed with asthma
[5]. Its prevalence in this country has been increasing
over the last 20 years [3]. Worldwide, asthma prevalence
rates have been rising on average by 50% every decade
[3]. Notably, asthma is the leading cause of hospital
admissions in the overall Canadian population [3,6],
the leading cause of absenteeism from school, and the
third leading cause of work loss [3]. Each year, there
are 146,000 emergency room visits due to asthma
attacks in Canada [3]. Asthma is also a major cause of
hospitalization [7] among the estimated 13% of Canadian
children who suffer from the disease [8].
High prevalence in conjunction with significant asthma-
related morbidity leads to a heavy clinico-economic and
humanistic burden of asthma in Canada [9,10]. Healthcare
utilization and costs are even higher when management
and control of the disease are suboptimal [11]. The direct
and indirect costs associated with asthma are expected
to rank among the highest for chronic diseases due to
the significant healthcare utilization associated with the
disease [9] and asthma’s detrimental impact on physical,
emotional, social, and professional lives of sufferers [12].
This systematic review is the first to consolidate and
summarize the literature (from 2000–2011) encompass-
ing not only the clinical and economic, but also the hu-
manistic burden of asthma in Canada. It, thus, provides
a holistic overview of the weight this disease poses to
the healthcare system, patients and society. Specifically,
this systematic literature review unveils the direct and
indirect costs of asthma per patient, the key drivers of
healthcare resource utilization, and the humanistic im-
pact of asthma on patients’ quality of life (QoL), which
cannot be inferred from clinical measures [13]. This
information, consolidated in a single review, can be of
value to payers, policy makers and healthcare providers
in making decisions pertaining to the management and
treatment of asthma.
Methods
We conducted a search of the PubMed, EMBASE, and
EMCare databases to identify original research (cross-
sectional, observational, or longitudinal studies on the
burden-of-illness and cost-of-illness) published from
2000 to 2011 on the burden of asthma in Canada. Re-
view articles, letters, editorials, commentaries, studies
reporting summaries of meeting proceedings or confer-
ences, abstracts or posters presented at scientific meet-
ings, and studies assessing the efficacy or effectiveness ofspecific interventions were not included. The time frame
was selected to reflect more recent developments in the
treatment and management of asthma in Canada.
Each search was conducted using controlled vocabu-
lary and key words, with “asthma” as the main search
concept. Search terms included “Canada,” “cost of ill-
ness,” “hospitalization,” “utilization,” “burden of illness,”
“quality of life,” “sickness impact profile,” and “health-
care cost.” Appendix shows the detailed search strategies
for each topic area. Searches were limited to articles
published in English and studies involving humans.
Studies were restricted to Canada.
Titles and abstracts of articles identified were carefully
screened in the initial review for relevance to the topic.
At the second review, articles were selected for inclusion
based on predefined acceptance criteria, which included
relevant patient population (ie, adults/children diag-
nosed with asthma) and appropriate study design and
outcome measures (patient- and population-level). Two
independent reviewers determined whether studies met
the inclusion criteria, and discrepancies between re-
viewer decisions were resolved in consensus.
Reasons for study exclusions were recorded. For arti-
cles that met predefined inclusion/exclusion criteria, the
quality of the studies was assessed using methodological
checklists provided in the NICE Guidelines Manual [14]
and the STROBE (STrengthening the Reporting of OBser-
vational studies in Epidemiology) guidelines [15,16]. Key
data elements were abstracted and tabulated in summary
tables: year and type of study, number of study subjects,
asthma definition, characteristics of study population, out-
comes evaluated, results, and overall conclusions of the
study.
Reported costs were inflated to 2011 Canadian dollars
(CAD) using the Consumer Price Index from Statistics
Canada [17].
Results
Figure 1 depicts the step-by-step study selection process.
The MEDLINE, EMBASE, and EMCare database searches
yielded 320 citations, 230 citations, and 20 citations,
respectively.
In the first-level selection process (based on the infor-
mation presented in the article abstracts) for the clinico-
economic burden, 503 of the 570 citations were rejected:
174 reported inappropriate outcomes (i.e., outcomes that
were not aligned with the outcomes of interest), 150 due
to inappropriate disease state (eg, the studies focused on
other chronic respiratory diseases or included only a
small number of the subjects with asthma), and 91 due
to inappropriate study design. Other reasons for rejec-
tion during the first-level selection process are shown in
Figure 1. Of the 67 full-text articles retrieved for poten-
tial inclusion, 34 were excluded during the second-level
Figure 1 Process for studies to be included in the review.
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Thus, 33 articles fulfilled all criteria and were included
in the clinico-economic burden review (Figure 1).
After duplicates were removed, 309 studies were iden-
tified by the humanistic burden literature searches from
the 3 databases. Of these, 288 studies were excluded
during the first-level selection for inappropriate disease
state (n = 44), inappropriate outcome measure (n = 60),
inappropriate study design (n = 96), jurisdiction (n = 9),
inappropriate patient population (n = 14), treatment
comparator (n = 26), because data could not be extracted
in the required format (n = 38), or because they were du-
plicate studies (n = 1).Twenty-one studies were selected
for potential inclusion in the review. During the second-
level selection, full-text articles were reviewed and a fur-
ther 7 were excluded for inappropriate outcome measure
(n = 1), study design (n = 2) or jurisdiction (n = 4). Four-
teen articles fulfilled all criteria and were included in the
humanistic burden review (Figure 1).
Table 1 depicts the quality assessment of the articles
on clinical, economic, and humanistic burden using
STROBE tools, and Table 2 summarizes quality assess-




Of the 33 studies meeting all criteria for inclusion, 23
contained clinical burden data only, 7 had information
on both clinical and economic burden of asthma, and 3
had data on the economic burden of asthma only.
Of the 30 studies on clinical burden, 1 was a case–
control, 22 were cohort, and 7 were cross-sectionalstudies. Characteristics of studies reporting on clinical
burden are shown in Table 3.
Most studies clearly reported the study design (97%),
setting (100%), participants (87%), and statistical
methods employed (70%). However, less than half re-
ported on potential sources of bias and confounding fac-
tors or how missing data was handled. Furthermore, less
than half of the studies reported on how loss to follow-
up was addressed in both the methods and results sec-
tions, or how sensitivity analyses were conducted. Main
results for outcomes data were appropriately reported in
97 % of the clinical burden studies, and more than 90%
met the STROBE criteria for appropriate quality discus-
sion. Most (77%) gave the source of study funding and
the roles of the funders. (Tables 1 and 2).
Studies employed a variety of definitions for asthma, in-
cluding ICD codes, physician visits and/or hospitalizations
for asthma (based on billing codes), asthma medication
prescriptions filled, and patient self-report. We report the
definitions used, but these definitions were not reconciled
in this review. When asthma was defined by the presence
of ICD codes, it was considered to be narrowly defined,
whereas a broad asthma definition included visits for an
asthma-related diagnosis and asthma-related hospitaliza-
tions among the discharge diagnoses.
Key findings on clinical burden
Hospitalizations
Table 4 provides an overview of hospitalization rates for
adult and pediatric patients with asthma in Canada. Re-
ported rates of hospitalization for asthma varied widely
according to age, geographic region, gender, and asthma
medication use. In a large cohort study spanning over
Table 1 Summary of quality assessment (using STROBE assessment tools) of the articles included
Report section Item Item
#
% articles with STROBE criteria not met
Clinical burden Economic burden Humanistic burden
Title and abstract Title 1a 20% 40% 10%
Abstract 1b 13% 30% 0%
Introduction Background/rationale 2 0% 0% 0%
Objective 3 0% 0% 0%
Methods Study design 4 3% 10% 0%
Setting 5 0% 0% 0%
Participants 6a 13% 10% 0%
6b 30% 10% 10%
Variables 7 23% 30% 30%
Data sources/measurement 8 10% 10% 0%
Bias 9 53% 40% 40%
Study size 10 20% 30% 30%
Quantitative variables 11 13% 20% 20%
Statistical methods 12a 30% 30% 10%
12b 47% 60% 20%
12c 70% 60% 50%
12d 60% 60% 30%
12e 77% 50% 80%
Results Participants 13a 40% 50% 30%
13b 63% 60% 30%
13c 73% 80% 50%
Descriptive data 14a 37% 50% 20%
14b 77% 80% 60%
14c 27% 20% 20%
Outcome data 15 3% 10% 0%
Main results 16a 27% 30% 0%
16b 63% 70% 20%
16c 40% 70% 30%
Other analyses 17 37% 20% 60%
Discussion Key results 18 0% 0% 0%
Limitations 19 7% 20% 20%
Interpretation 20 3% 10% 0%
Generalizability 21 3% 10% 20%
Other Funding 22 23% 40% 20%
Table 2 Summary of quality assessment (using NICE RCT
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Saskatchewan Health databases on asthma patients
from that province aged 5–44 between 1975 and 1991
and found that the overall rate of asthma hospitalization
was 42 per 1000 asthma patients per year in patients
with at least 1 year of follow-up. The rate was higher
(48 per 1000) in patients receiving at least 3 anti-asthma
medication prescriptions in any 1 year. During the vari-
able follow-up period (up to 4 years), regular use of in-
haled corticosteroids (ICS) was associated with a 31%
Table 3 Characteristics of clinical burden studies included in the review







Determine direct medical costs of asthma-
related healthcare in British Columbia
5 to 55 years Narrow: ICD-9 493.x Broad: visits for an
asthma-related diagnosis; hospitalizations with
asthma among the discharge diagnoses≥4 asthma prescriptions in 1 year
≥1 asthma hospitalization
≥2 physician visits for asthma
Blais et al. 2011
[18] 1998 - 2005
RAMQ database, Determine relationship between better
use of LTRA and asthma exacerbations in
children
5-15 years Moderate or severe asthma exacerbations - an
ED visit for asthma, a hospital admission for
asthma, or a dispensed short-course (14 days)
prescription of oral corticosteroids
Diagnosed asthma







Describe the epidemiology of asthma
presentations to EDs for 3 main regions
in the province of Alberta
All people registered under the AHCIP at any
time in a given year
ICD-9 code 493.x or ICD-10 code J45.x as the
first or second diagnosis fields in the ACCS
Crighton et al. 2001 [20] Apr 1,
1988 to Mar 31, 2000
DAD database at CIHI, Examine the seasonal patterns and
trends of asthma hospitalizations in
relation to age and gender
NR ICD-9-CM code 493
Ungar et al. 2011 [21] Nov 1,
2000 to Mar 31, 2003
Interview data linked to
administrative
healthcare data.
Identify factors associated with asthma
exacerbation causing ED visits or
hospitalizations related to health status,
socioeconomic status (SES), and drug
insurance









Examine inequalities between SES groups
with respect to rates of ACSC-
hospitalizations
Acute care cases of 0 to 75 years; asthma in
children for age <20 years
NR
Blais et al. 2009 [18] 2002 - 2004 RAMQ database Compare the use of healthcare services
between new users of
budesonide/formoterol and F/S
Asthma patients aged 16 to 65 years ≥1 claim
for combination therapy in 2002 or 2003 and
no claims for combination therapy for ≥1 year
prior to first claim
ICD-9 codes 493.0, 493.1, 493.9




Describe the epidemiology of asthma
presentations to EDs made by adults in
the province of Alberta, Canada
Asthmatic individuals aged 18 years ICD-9 493.x or ICD-10 J45.x
To et al. 2008 [24] 1994 - 1998 DAD database from
CIHI, OHIP records,
RPDB database
Describe the prevalence of asthma;
all-cause mortality; physician visits and
hospitalizations for asthma and all causes;
and seasonal and geographical variation of
healthcare utilization in children
Children aged 0 to 9 years At least 1 asthma hospitalization or 2 asthma






Compare clinical characteristics and use
of medical resources between subjects
with OA, WEA, and WRA






















Table 3 Characteristics of clinical burden studies included in the review (Continued)
To et al. 2007 [26]
1994 to 2006
HMDB database from
CIHI, OHIP records, RPDB
database;
Examine and predict the persistence of
childhood asthma
Children born in 1994 diagnosed with asthma
before their 6th birthday, followed up until
their 12th birthday
1 asthma hospitalization or 2 asthma physician
claims within 3 years prior to age 6 years (ICD-
9 493 or ICD-10 J45). Persistent asthma - add-
itional claims during follow-up Remission
asthma - no additional claims
Agha et al. 2007 [27] 1993 - 2001 DAD database at CIHI,
SES from the 1996
Census data
Examine socioeconomic disparities in
ACS and non-ACS admissions among
birth cohorts in a universal health
insurance setting
Children born alive in Toronto during
1993–2001
The most responsible diagnosis in the CIHI
DAD DB
Gershon et al. 2007 [2] 1994/95
to 2001/202
DAD from CIHI, OHIP Understand the burden of asthma Asthma patients from ON, aged 0–39 years 1 DAD hospitalization record or 2 OHIP claims




CIHI Assess regional differences in ED visit
rates and hospitalizations for asthma
ED visits for asthma ICD-10 code J45.x
Dik et al. 2006 [29] 1985 - 1998 Manitoba administrative
healthcare data
Study 14-year trends in utilization of
physician resources for asthma and com-
pare them to trends for allergic rhinitis
NR ICD-9-CM code 493
Sin et al. 2001 [30] FY 1992 - 1996 CIHI, drug claims,
physician billing, and
mortality databases
Determine the impact of ICS on
rehospitalization for asthma and all-cause
mortality rates in elderly patients
Asthmatic patients, aged ≥65 years, who had
been hospitalized with a most responsible
diagnosis of asthma in the past 5 years
ICD-9 codes 493.0, 493.1, and 493.9
Prospective cohort studies
Rowe et al. 2010 [31] 2004 –
2005
Interviews Describe factors associated with
admission to hospital for acute asthma
after ED treatment
Patients aged 18 to 55 years diagnosed with
asthma
Patient-reported
Sin et al. 2003 [32] 1985, 1988 AHCIP data, Determine the relationship between SES
and ED visits for asthma in a free access
healthcare system.
Children born 1985 to 1988 followed for 10
years
ICD-9 code 493.x
Ungar et al. 2001 [33] May - Oct
1995
Telephone interviews at
1, 3, and 6 months,
Assess the cost of asthma care at the
patient level in children from the
perspectives of society, the Ontario
Ministry of Health, and the patient.
Patients or caregivers filling prescriptions for
bronchial inhalers
Probable asthma - a prescription for a
bronchial inhaler medication in the last month
(bronchodilator or corticosteroid) and
reported experiencing shortness of breath,
wheeze, or recurrent cough in the past




Estimate the average direct cost of illness
for 4 cardiorespiratory conditions
ED visitors who completed follow-up
interviews
ED visit records
Rowe et al. 2007 [23] 1996-1998 Structured ED interview
and telephone follow-
up 2 weeks later
Compare ED asthma management and
outcomesbetween Canada and US
Patients aged 2 to 54 years who presented
with acute asthma in ED
NR
Cross-sectional studies
Boulet et al. 2008 [35] April -
August 2004,
Telephone survey Assess the influence of current and
former smoking on self-reported asthma
control and healthcare use
Adults aged 18 to 54 years with physician-
diagnosed asthma for ≥6 months
Patient-reported or physician-diagnosed
asthma




Describe the quality of asthma care using
a set of proposed quality indicators
Saskatchewan residents who had a valid
health insurance number
Over 1-year period: ≥3 prescriptions for anti-
asthma drug or ≥2 physician claims (ICD-9 code





















Table 3 Characteristics of clinical burden studies included in the review (Continued)
ICD-10 J45.x) or ≥1 claim for physician services
or hospitalization for asthma plus ≥1 pharmacy
claim for an antiasthma drug
Iron et al. 2003 [37] 1994/1995 CNPHS data, OHIP Determine the association between
demographics, access to care, SES, and
need (comorbidities) with actual family
physician costs
Survey respondents aged ≥25 years
consenting to share HC# and responses with
MOHLTC
Self-reported
Anis et al. 2001 [38] 1995 Ministry of Health
administrative
databases
Determine whether excessive use of
SABA, in conjunction with underuse of
ICS, would be a marker for poorly
controlled asthma and excessive use of
healthcare resources
Asthma patients aged 5 to 50 years for whom
≥1 prescription for a SABA was filled in 1995
Patients filling SABA prescriptions; for
hospitalizations, ICD-9 code 08 (diseases of the
respiratory system)
Baibergenova et al. 2005 [39]
April 1, 2001 to March 31, 2004
Examine the pattern and strength of
seasonal fluctuations in ED visits due to
asthma
Asthma patients with ED visits for asthma or
status asthmaticus
ICD-9 code 493.x or ICD-10 J45.0–J45.9
Lynd et al. 2004 [40] NR Survey Assess the association between SES and
SABA use, controlling for asthma severity
Asthmatic patients aged 19 to 50 years
residing in the Greater Vancouver Regional
District of British Columbia
NR
Case–control study
Suissa et al. 2002 [41] 1975 - 1997 Saskatchewan Health
DB
Assess whether regular use of ICS
prevents asthma hospitalizations
Source cohort: subjects aged 5–44 years
receiving ≥3 prescriptions of an antiasthma
medication in any 1-year period Full cohort: all
subjects with ≥1 year follow-up, irrespective
of whether they were admitted to hospital for
asthma during the baseline year
Primary discharge diagnosis of asthma (ICD-9
codes 493.0, 493.1, or 493.9)
Health economic analysis
Seung et al. 2005 [42] 2004 NACRS at CIHI, OCCI,
MOHLTC billing
Determine the use of urgent care
resources and annual costs for the
uncontrolled asthmatic population in
Canada
NR ICD-9 Code 493
ACCS=ambulatory care classification system, ACSC=ambulatory care-sensitive conditions, AHCIP=Alberta Healthcare Insurance Plan, CIHI=Canadian Institute for Health Information, CNPHS=Canadian National Population
Health Survey, DAD=Discharge Abstract Database, ED=emergency department, HMDB=Hospital Morbidity Database, ICS=inhaled corticosteroid, ICD=International Classification of Diseases, LTRA=leukotriene receptor
antagonist, MOHLTC=Ministry of Health and Long Term Care, NACRS=National Ambulatory Care System, NR=not reported, OA= occupational asthma, OCCI=Ontario Case Costing Initiative, OHIP=Ontario Health Insur-





















Table 4 Rate of hospitalizations for asthma patients in Canada
Study Number of patients Patient descriptor Year Hospitalizations for asthma
Per patient
per year





7,494 ≥1 exacerbations in the year prior to treatment initiation,
ICS
1998-2005 0.03
≥1 exacerbations in the year prior to treatment initiation,
LTRA
0.06
19,861 No exacerbation in the year prior to treatment initiation: ICS 0.005





490 Asthmatic children 2000-2003 0.25§
To et al. 2008 [24] 56,737 0-2 years 1998/1999 86.7
99,163 3-5 years 27.3
141,305 6-9 years 10.9
297,205 Overall 30.9









158,516 Narrow asthma definition€ 1996-2000 0.016
Broad asthma definition¥ 0.03
Lemiere et al.
2007 [25]




4,671 Appropriate use† 1995 0.07(0.34)









24,616 (24,180 of whom were still alive and living in the
region the following year)
























Table 4 Rate of hospitalizations for asthma patients in Canada (Continued)
Lougheed et al.
2006 [28]
574,304 children and 1,194,095
adults in Ontario
Patients with an ED disposition diagnosis of asthma in a
stratified sample of 16 hospitals




30,569 Source cohort†† 1975-1997 48
4,673 Full cohort‡‡ 42.4
Seung et al.
2005 [42]
NR Asthma patients 2004 1.43**
§Calculated as 124 hospitalizations for 490 patients.
*Calculated as the rate per 100 patients x 10.
**Calculated as (the rate per 100,000 patients) / 100.
€Narrow asthma definition: ICD-9 493.x.
¥Broad asthma definition: visits for an asthma-related diagnosis; hospitalizations with asthma among the discharge diagnoses.
†Appropriate use (low-dose SABA + high-dose ICS).
‡Inappropriate use (high-dose SABA + low-dose ICS).
††Source cohort: subjects 5–44 years receiving ≥3 prescriptions of an anti-asthma medication (beclomethasone, budesonide, epinephrine bitartrate, fenoterol, flunisolide, ipratropium bromide, isoproterenol, ketotifen,
metaproterenol, nedocromil, procaterol, salbutamol, sodium cromoglycate, terbutaline, triamcinolone acetate, or any compound of theophylline) in any 1 year period.
‡‡Full cohort: all subjects with at least 1 year follow up, irrespective of whether or not they were admitted to hospital for asthma during the baseline year.
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and a 39% reduction in the rate of readmissions for the
cohort with more severe asthma who had been previ-
ously hospitalized for the condition during the 1-year
baseline period. The study investigators concluded that
their findings emphasize the importance of regular use
of inhaled corticosteroids to avoid hospitalizations.
In a retrospective cross-sectional study of asthma
patients aged 5–54 years using health databases in
Saskatchewan, Klomp et al. [36] found that, in 2002–03
and 2003–04, the hospitalization rate for asthma was 10.9
per 1000 patients per year.
Agha et al. [27], using data on hospital admissions from
the Dischrage Abstract Database of the Canadian Institute
for Health Information, reported 8,583 asthma hospitaliza-
tions among 255,284 pediatric patients (a rate of 33.6 in
1000 patients) born between 1993 and 2000 in Toronto.
A significantly lower rate was reported in Canada by
Seung et al. [42], who cited figures reported by the Pub-
lic Health Agency of Canada of 143 asthma-related hos-
pitalizations per 100,000 adult and pediatric patients, or
1.43 in 1000, in 1998 (with an additional 3.7 per 1000,
many of whom had underlying asthma, hospitalized for
influenza/pneumonia).
Higher rates were reported for hospital admissions of pa-
tients who initially presented to the emergency department
(ED). Lougheed et al. [28] reported that 6.9% of adults and
10.8% of children who presented to the ED with asthma
were admitted to the hospital.
According to the results of a study based on interviews
with parents, 25% of the pediatric study population (124
of 490 patients) had been hospitalized for asthma in the
previous 12 months [21]. In a large study utilizing data
from Quebec administrative databases, children aged 5
to 15 years with at least 1 exacerbation in the year prior
to treatment initiation with ICS or leukotriene receptor
antagonists (LTRA) had higher rates of hospitalizations
than those with no exacerbation in the previous year
(0.03 vs. 0.005 hospitalizations per patient per year in
the ICS group and 0.06 vs. 0.003 per patient per year in
the LTRA group) [43]. The proportion of prescribed
days covered was significantly higher in the LTRA group
than in the ICS group (52% vs. 34%) [43].
In a study of all Ontario babies born during the year
1994 who were diagnosed with asthma before their sixth
birthday, there was a decreasing trend in hospitalization
rates with age, from 86.7 per 1000 patients per year in the
0 to 2 years age group to 27.3 per 1000 patients for those
aged 3 to 5 years and 10.9 per 1000 for those aged 6 to
9 years. These investigators also found that children with
persistent asthma had more than one and a half times
higher hospitalization rates compared with patients whose
asthma was in remission (63 per 1000 patients vs. 39 per
1000 patients per year) [26].In another Ontario-based study that examined asthma
seasonality and hospitalizations by gender and age group
over a 12-year period, results of spectral analysis re-
vealed that hospitalization rates for children with asthma
were highest in September and October each year across
the 12-year period, with a 2 to 3-times higher rate of
hospitalizations in boys (180 per 100,000) than in girls
under the age of 9 years [20]. However, among children
older than 9 years, female hospitalizations exceeded
those of males [20].
The large variations in reported rates of hospitaliza-
tions may be due to variations in ED visit rates and/or
hospital admission percentages [28]. Hospital admissions
appear to follow a bimodal age distribution pattern, with
the very young and the elderly more likely to be admit-
ted [28]. Other factors that can drive up rates of
hospitalization in particular regions or among specific
populations are higher disease prevalence, greater dis-
ease severity, multiple comorbidities, and barriers to
care associated with socioeconomic status [27].
ED visits
The number of asthma emergency visits varied by age,
type of treatment, social status, and living area (urban/
non-urban). Table 5 summarizes ranges and mean num-
bers of annual ED visits for asthma, as reported in the
included studies. According to several studies, both chil-
dren and adults with asthma averaged less than 1 ED
visit per patient per year [21,23,28]. ED visit rates were
significantly higher in women than in men and, overall,
the rate of ED visits increased with age [28].
In a study investigating the impact of appropriate use (ac-
cording to the 1999 Canadian asthma consensus report and
the National Heart, Lung and Blood Institute Guidelines
for the Diagnosis and Management of Asthma) and compli-
ance with asthma medications in adults, the rate of ED
visits for asthma was twice as high for patients not using
asthma medication appropriately (high-dose SABA plus
low-dose ICS) than for those using it appropriately (low-
dose SABA plus high-dose ICS) [38].
Rosychuk et al. [19] examined trends in asthma-
related ED visits by more than 45,000 children aged
<18 years during the period from April 1999 to March
2005 and did not observe decreased ED presentation
rates over time, despite improvements in treatment
and availability of guidelines. The standardized rates
remained stable over time, with 21.1 visits occurring per
1000 patients in 1999/2000 versus 19.8 per 1000 in
2004/2005.
Sin et al. [30,44] reported that elderly asthmatic pa-
tients using ICS post-discharge from hospital were 29%
less likely to be readmitted to hospital for asthma and
39% less likely to experience all-cause mortality com-
pared with those who did not receive ICS post-discharge










27,355 Children, 5–15 years, on ICS or LTRA therapy, by # of
exacerbations in the previous year, 1998-2005
0.04* (on LTRA, no exacerb.
in the previous year)
0.32* (on ICS, 1+ exacerb.
in the previous year)
Lougheed et al.
2006 [28]
4,674 Ontario patients, <20 years, 2001-2002 13.6 [8.7 to 25.2]**
Sin et al.
2003 [32]
90,845 Children, 0–10 years, 1985–1988, by SES 6 [0 to 31]** (very poor) 7 [0 to 34]** (non-poor)
Ungar et al.
2001 [33]




elderly asthmatic, by ICS therapy 1 (1.2)* (not using ICS) 1.5 (1.3)* (using ICS)
Rowe et al.
2009 [45]
48,942 Adults, 1999/2000 to 2004/2005 6.7** (2004/2005) 9.7** (1999/2000)
Lemiere et al.
2007 [25]
351 Adults, work-related asthma, 2001-2004 0.2 (0.7)* (NWRA) 0.3 (0.8)* (WRA)
Lougheed et al.
2006 [28]
3,993 Adults, ≥20 years, 2001-2002 3.9 [1.7 to 10.1]**
Anis et al.
2001 [38]






3,031 Canada and US ED visits, 1996-1998 0(0–3)§ (US) 1(0–3)§ (Canada)
Baibergenova
et al. 2005 [39]




21,700 Asthma patients, Alberta, 2004-2005 6.9(6.6-7.0)*** (Calgary) 15.1(15.1-15.9)*** (NMU)
*Per patient.
**Mean [range] per 1000 patients.
***Mean (95%CI).
§Median (IQR).
∫Appropriate use (low-dose SABA + high-dose ICS); Inappropriate use (high-dose SABA + low-dose ICS).
†Calculated from 99,054 ED visits due to asthma were made by 73,566 adults.
ICS=inhaled corticosteroid, LTRA=leukotriene receptor antagonist, NMU= non-major urban areas, NWRA=non-work-related asthma, SABA=short-acting β-agonist,
WRA=work-related asthma.
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bidity, and use of other antiasthma medications were
controlled for, ICS use was associated with a 32% relative
rate reduction for recurrent hospitalization or all-cause
mortality (95% CI 23%-39%). Among patients who re-
ceived at least 1 prescription for ICS within 1 year prior
to the index hospitalization, the use of ICS 90 days post-
discharge was associated with a 41% decrease in recur-
rent asthma-related hospitalizations or deaths compared
with non-use of ICS (95% CI 32%-49%).
Sin et al. [32] also reported on ED visits in children born
in Alberta between 1985 and 1988, stratified by SES, and
found that very poor children were 23% more likely to have
had an ED visit for asthma compared with children from
non-poor families (RR 1.23; 95% CI 1.14 – 1.33). Very poor
children had a similar risk of having an asthma-related ED
visit as poor children (RR 0.97; 95% CI 0.91 – 1.04).Physician visits
Studies that reported rates of asthma-related physician
visits are summarized in Table 6. In a population-based
study evaluating 14-year trends in Manitoba in utilization
of physician resources for asthma, Dik et al. [29] found
that, between the period 1985–1988 and 1994–1998, the
greatest increases in prevalence and incidence of physician
visits for asthma occurred in the youngest age groups,
while in adults the prevalence and incidence changed little
with time. However, the average rate of physician visits for
asthma decreased from 1.66 visits per patient-year in
1985–1988 to 1.40 in 1989–1993, and further to 1.16 visits
per patient-year in 1994–1998.
More former or current smokers than non-smokers
visited their physician [35], as did patients with work-
related asthma vs. non-work-related asthma [25] and
patients inappropriately using their asthma medication
Table 6 Rate of physician visits in Canada
Study Number of patients Patient descriptor Year Physician visits for asthma§
Children
To et al. 2008 [24] 56,737 0-2 years 1998/1999 2.2
99,163 3-5 years 1.1
141,305 6-9 years 0.8
297,205 Overall 1.2
Ungar et al. 2001 [33] 339 GP 1995 3.6
Respiratory specialist 2.1
Adults
Boulet et al. 2008 [35] 514 Non-smoker 2004 43% had ≥1
268 Former smoker 49% had ≥1
108 Current smoker 47% had ≥1
Lemiere et al. 2007 [25] 351 (WEA: 145, OA: 206) WRA 2001-2003 4.1(4.3)
NWRA 1.2(1.7)
Sadatsafavi et al. 2010 [10] 158,516 Narrow asthma definition 1996-2000 1.86
Broad asthma definition 3.85
Iron et al. 2003 [37] 230* Asthma patients 1994/1995 4.3**
Sin et al. 2001 [44] 6,254 No ICS (elderly) 1992-1996 3.9(2.2)
ICS (elderly) 4(2.2)
Anis et al. 2001 [38] 4,671 Appropriate use† 1995 14.9(15.9)
763 Inappropriate use‡ 16.7(19.3)
Anis et al. 2000 [34] 733 Physician visits in ED 1994-1995 1.0(1.3)
Blais et al. 2009 [18] 1264 BUD/FORM 2002-2004 7.5(7.4)
1264 FP/SM 7.3(7)
All ages








§ Per patient per year, mean (SD).
*Asthma patients, calculated as 6% of 3830 NPHS responders.
**Median.
†Appropriate use (low-dose SABA + high-dose ICS).
‡Inappropriate use (high-dose SABA + low-dose ICS).
BUD/FORM=budesonide/formoterol, FP/SM=fluticasone propionate/salmeterol, GP=general practitioner, ICS=inhaled corticosteroid, NR=not reported, NWRA=non-work-
related asthma, WRA=work-related asthma.
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http://www.biomedcentral.com/1471-2466/13/70[38]. Among elderly patients, the rate of physician
visits for asthma was not influenced by treatment with
ICS [44].
Children in an Ontario-based study who were born in
1994 and diagnosed with asthma before age 6, and whose
asthma persisted until age 11 (as determined by the pres-
ence of claims for physician and/or hospital visits between
the ages of 6 and 11), had a higher rate of physician visitsthan those in remission (60 vs. 46.9 visits per 100 patients
per year) [26].
Medication prescriptions
Lynd et al. [40] reported that 27% of patients receive oral
corticosteroids, 17% use no ICS, 47% receive less than 4
ICS canisters per year, 29% use 5 to 12 canisters, and 8%
use more than 12 ICS canisters per year.
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scriptions per patient per year than adults [11,21,38]. Pa-
tients with inappropriate use of asthma medications (ie,
those who were non-adherent to guidelines recom-
mended in the 1999 Canadian asthma consensus report
and the National Heart, Lung and Blood Institute Guide-
lines for the Diagnosis and Management of Asthma) re-
ceived more than double the number of prescriptions
per patient per year (mean [SD] 7.5 [4.9]) compared with
those who used asthma medication appropriately (mean
[SD] 3.3 [1.9]) [38].Economic burden studies
Overview
Ten studies evaluated the economic burden of asthma in
Canada (5 cohort studies, 4 cross-sectional, and 1 eco-
nomic analysis). Costs in the economic analysis were cal-
culated for 1,350,871 persons, based on the 1998/1999
estimate that 57% of 2,389,085 persons aged ≥4 years
had uncontrolled asthma.
More than 80% of these studies met the STROBE criteria
for appropriate quality discussion. Most studies clearly re-
ported the study design (90%), setting (100%), participants
(90%), and statistical methods employed (70%). However,
less than half reported on potential sources of bias and con-
founding factors or how missing data was handled and how
loss to follow-up was addressed in both the methods and
results sections or sensitivity analyses conducted. Most
studies (60%) gave the source of funding and the role of the
funders for their study (Table 1).
Asthma cases were identified using ICD codes or
clearly stated diagnosis, retrospective physician visits,
hospitalizations for asthma, and/or asthma medication
prescriptions filled or patient self-report of asthma diagno-
sis or symptoms. There was available evidence on both the
direct and indirect components of the economic burden of
asthma in Canada. The overall burden varied based on
whether studies reported costs from the perspective of an
individual patient with asthma or costs at the population
level. Few Canadian studies reported a cost per episode of
acute asthma, and no studies reported the cost per patients
overall. Five studies reported data on the direct costs of
asthma at the patient-level. Three of these studies reported
asthma costs per asthma patient [10,24,37], while 2 studies
reported asthma costs per acute asthma episode [34,42].
Three studies reported population-level direct costs for
asthma [10,24,42]. Study characteristics are presented in
Table 7.Key findings on economic burden
All costs reported in this section are in 2011 Canadian
dollars.Patient-level direct costs
Based on data from administrative databases in British
Columbia, average total annual direct cost estimates in
the general population ranged from $366.17 to $490.88
per asthma patient (Table 8) [10].
Ungar and colleagues [33] estimated the total cost of
asthma in children aged 0–14 years in Ontario to be
$883.48 per child from the healthcare perspective
(Table 8). Adjusted annual societal costs per patient (1995
Canadian dollars) ranged from $1,122 in children aged 4–
14 years to $1,386 in children younger than 4 years. From
the Ministry of Health perspective, adjusted annual costs
per patient were $663 in children over 4 years and $904 in
younger children. Adjusted annual costs from the patient
perspective were $132 in children over 4 years and $129
in children under 4 years.
During the period from 1996 – 2000, average hos-
pitalization costs ranged from $67.90 to $136.87 per patient
per year in the general population in British Columbia
(aged 5 to 55 years), depending on the definition used to
categorize asthma-related hospitalizations [10]. The esti-
mated average annual hospitalization cost for asthma in
children was $682.21 per patient in Ontario [33].
Sadatsafavi et al. [10] reported that ED visits made by
asthma patients in the general population could cost the
healthcare system anywhere between $66.35 and $122.09
per visit, depending on the asthma definition used. The
reported range of average costs for ED visit per acute
asthma episode was $209.48 to $274.48 [10,33]. Ungar
and colleagues [33] estimated the average annual cost
for ED visits in children to be $15.68.
The average costs for physician visits per acute asthma
episode were estimated to range from $31.72 [34] in an
economic modeling study using prospectively collected re-
source utilization data (9/1/94 to 8/31/95) from hospital
emergency department visitors to $31.91 in the economic
analysis by Seung and Mittmann [42]. Average costs of
$98.02 and $70.57 annually per pediatric patient were re-
ported for family physician and specialist visits, respectively,
in the prospective study by Ungar et al. [33]. Although the
cost per respiratory specialist visit was higher than the cost
per family physician visit ($105.40 vs. $51.40 for the first
visit and $23.10 vs. $16.25 for an additional visit), nearly
twice as many patients (271, or 80%) reported visiting a
family physician, at an average annual use of 3.6, compared
with a respiratory specialist (141, or 42% of patients), at an
average annual use of 2.1 [33]. A study conducted in On-
tario demonstrated that outpatient claim costs for persons
with asthma exceeded those for persons without asthma by
about $200 per person per year [2].
With regard to asthma medication prescriptions, the
administrative database study from British Columbia es-
timated the average annual cost for asthma medication
in the general population to be $231.92 per patient [10].
Table 7 Characteristics of economic burden studies included in the review
Reference/Study
period
Data source Study objective Inclusion criteria Asthma definition
Retrospective cohort studies
Sadatsafavi et al.
2010 [10] 1996 - 2000
Administrative
healthcare data
Determine direct medical costs of asthma-related
healthcare in British Columbia
Aged 5 to 55 years Narrow definition: ICD-9 code 493.x Broad definition: visits for
an asthma-related diagnosis; hospitalizations with asthma
among the discharge diagnoses≥4 asthma prescriptions in 1 year
≥1 asthma hospitalization
≥ 2 physician visits for asthma




Assess direct costs of CLI and CFI for OA and their









Describe prevalence of asthma, all-cause mortality,
physician visits, and hospitalizations for asthma and all
causes; seasonal and geographical variation of health-
care utilization in children
Children aged 0–9 years ≥1 asthma hospitalization or 2 asthma OHIP claims within 3
years
Prospective cohort studies
Ungar et al. 2001 [33]
May - Oct 1995
Telephone
interviews at 1, 3,
and 6 months
Assess cost of asthma care at the patient level in
children from the perspectives of society, the Ontario
Ministry of Health, and the patient
Patients or caregivers filling
prescriptions for bronchial inhalers
Probable asthma - a prescription for a bronchial inhaler
medication in the last month (bronchodilator or corticoster-
oid) and reported experiencing shortness of breath,
wheeze, or recurrent cough in the past
Anis et al. 2000 [34]
Sept 1, 1994 - Aug
31 1995




Estimate average direct cost of illness for 4
cardiorespiratory conditions




Kohen et al. 2010
[47] Fall 1998 and
Spring 1999
NLSCY Examine associations between asthma and school
functioning
Individuals aged 7–15 years with
complete data on the measures
of interest
Past-year wheezing or whistling in the chest and regular
use of inhalers
Boulet et al. 2008
[35] April - August
2004,
Telephone survey Assess influence of current and former smoking on self-
reported asthma control and healthcare use
Adults aged 18–54 years with
physician-diagnosed asthma for
≥6 months
Patient report of physician-diagnosed asthma




Determine the association between demographics,
access to care, SES, and need (comorbidities) with
actual family physician costs
Survey respondents aged ≥25
years consenting to share HC
number and responses with
MOHLTC
Self-reported
Thanh et al. 2009 [48]
2005
CCHS To estimate the cost of asthma-related productivity loss
days due to absenteeism and presenteeism* in Alberta
Survey respondents aged 18–64
years
Patient report of an asthma diagnosis
Health economic analysis





Determine the use of urgent care resources and the
annual costs of the uncontrolled asthmatic population
in Canada
NR ICD-9 code 493
* absenteeism=absent from work, presenteeism=at work but not fully functioning.
CCHS= Canadian Community Health Survey, CFI= compensation for functional impairment, CLI=compensation for loss of income, CNPHS=Canadian National Population Health Survey, HC=health card, MOHLTC=Ministry of





















Table 8 Summary of studies that reported patient-level total direct costs for asthma
Reference/Study period Age group Patient group Average total annual cost per patient Inflated 2011 $CAD
Retrospective cohort studies
Sadatsafavi et al. 2010 [10]
Apr 1996 - Mar 2000
5-55 yrs Narrow asthma definition $331.15 $366.17
Broad asthma definition $443.93 $490.88





Ungar et al. 2001 [33] May - Oct 1995 0-14 yrs Societal $1,079 $1,410.17
MOHLTC $676 $883.48
Patient $76 $99.33
MOHLTC, Ministry of Health and Long Term Care.
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http://www.biomedcentral.com/1471-2466/13/70Ungar et al. [33] estimated the average annual costs for
medication per patient in children to be $352.87 from
the societal perspective and $86.26 (2011 $CAD) from
the patient perspective. Estimated average medication
costs per acute asthma episode ranged from $5.29 to
$629.39 in these studies [10,33].
Population-level direct costs
The 1998–1999 healthcare cost for asthmatic children in
Ontario ($120 million, or $227.1 - $640.3 per child per
year, depending on age group) was considerably higher
than the total asthma cost for the general population (all
ages) of British Columbia during the period 1996 – 2000
(~$41.8 million, or $331 per patient per year) (Table 9)
[10,24].
Based on data from administrative healthcare data-
bases (April 1996 through March 2000), the total annual
population-level asthma cost estimates in the general
population in British Columbia ranged from ~ $46.3
million to $62.0 million , depending on the definition
of asthma used [10]. Between ~8.5 million and ~17.2
million of that was spent on asthma-related hospitaliza-
tions, ~8.4 million to ~15.5 million on physician/ED
visits, and ~15.4 million to ~29.3 million on asthmaTable 9 Summary of studies that reported population-level to
Reference/Study period Age group Patient g
Retrospective cohort studies
Sadatsafavi et al. 2010 [10] April 1996 - March 2000 5-55 yrs Narrow a
Broad ast





MOHLTC, Ministry of Health and Long Term Care.medications [10]. Medication costs represented the bulk
(63.9%) of the total cost, hospitalizations/ED visits com-
prised 17.8%, and physician visits accounted for 18.3% of
the total cost.
In Ontario, the total population-level costs for asthma
in children aged 0–9 years ranged from ~ $140 million
during 1994–1995 to ~ $120 million in 1998–1999 [24].
Patient-level indirect costs
About 50% of children missed 1–3 days of school (47.6%
in the group with low-severity asthma, 53.9% in those
with moderate severity, and 50.6% in the severe asthma
group), and 5.7% of the low severity, 5.3% of the moder-
ate severity, and 9.1% of the severe asthma patients were
absent for 7 or more days [47].
Malo et al. [46] evaluated a random sample of 8 to 10
accepted claims for occupational asthma per year from
1988 to 2002 in Quebec and found that the mean
cost of compensation for loss of income (CLI) across
the 15 years (not accounting for inflation) was $72,500
(median $40,700) and the mean cost of compen-
sation for functional impairment (CFI) was $11,700
(median $7,600). Median CLI costs were significantly
higher in men than women (69.9 vs 13.1), in workerstal direct costs for asthma
roup Total annual population cost Inflated 2011 $CAD
sthma definition $41,858,610 $46,285,583
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in workers taking inhaled steroids at diagnosis (92 vs 52)
and at reassessment (81 vs 35). Median CFI costs were
significantly higher for individuals being treated with in-
haled steroids at the time of diagnosis (14.0 vs 5.2) and
reassessment (13 vs 6).
Population-level indirect costs
In a population of ~1.5 million working-age individuals
in Alberta with an asthma prevalence of 8.5%, the num-
ber of asthma-related productivity lost work days ranged
from 441,728 to 533,363 in 1 year, at a cost of $78.1 to
$94.4 million in lost productivity [48].
Ungar et al. [49] reported productivity loss days (PLD)
without reporting actual indirect costs. They found that
annual PLD varied from 12 in employed persons to 20
in students, 22 in homemakers, retirees and the un-
employed, and 49 in disability pensioners. Annual PLDs
increased with increasing disease severity.
Humanistic burden studies
Overview
Fourteen articles reporting results from 13 studies were
retained for inclusion out of the 309 studies identified by
the humanistic burden literature search. Two were co-
hort studies, 8 were cross-sectional, and 4 studies were
RCTs. Only 1 of these was a pediatric study [50], which
assessed the impact of asthma medication on children
using the 3-domain Pediatric Asthma Quality of Life
Questionnaire (PAQLQ). No studies were identified that
reported utilities or QoL from a caregiver perspective.
QoL assessments focused on subgroups of the asthma
population, and studies had small numbers of partici-
pants. A variety of definitions were used to define
asthma including clinical diagnosis, presence of symp-
toms, and positive inhalation tests. Characteristics of
studies reporting on humanistic burden are detailed in
Table 10.
Overall, most studies on humanistic burden met good
reporting quality standards in accordance with STROBE
criteria (Table 1). However, less than half of the studies
reported how missing data and loss to follow-up was
handled or sensitivity or other analyses performed. Most
studies also met the STROBE criteria for appropriate
quality discussion (80%) and reported information on
study funding (80%).
The effect of psychiatric disorders on asthma control
and QoL in adults was examined in 2 studies [57,58].
Another 2 studies examined QoL by asthma severity and
chronicity [54,62]. Eleven studies used the 32-item
AQLQ to assess the impact of asthma on patients’ QoL
[51-56,58-63]. Other tools that were used to measure
the humanistic burden of asthma were the AQL-5D, the
EQ-5D, the SF-6D, the Health Utilities Index (HUI-3),the Asthma Control Questionnaire (ACQ), and the 8-
question St Georges Respiratory Questionnaire (SGRQ).
Key findings on humanistic burden
Depression and anxiety were prevalent among asthma pa-
tients and were associated with worse asthma control and
quality of life (QoL) [52]. Yacoub et al. reported a 50%
prevalence of anxiety and/or depression among 40 subjects
with occupational asthma [56]. In a study conducted by
Lavoie et al., 31% of 504 adults with physician-diagnosed
asthma met the diagnostic criteria for 1 or more psychiatric
diagnoses [57]. A study specifically looking at occupational
asthma also found that psychological distress and psychi-
atric disorders including depression, anxiety, and dysthymia
were associated with impaired QoL [63].
As one would expect, QoL became progressively worse
as disease severity increased [54,62]. Furthermore, QoL
was lower in asthma patients who had at least 1 other
chronic disease compared to those who had no other
chronic disease [54].
A study of 504 consecutive adults with physician-
diagnosed asthma reported that depressive and anxiety
disorders were both independently associated with de-
creased health-related QoL (as measured by AQLQ
scores), but only depressive disorders were independ-
ently associated with worse asthma control (as measured
by ACQ scores) [57]. Interestingly, having both depres-
sive and anxiety disorders did not increase the risk for
worse asthma control or decreased QoL [57]. According
to the study authors, this finding suggests that there is
no incremental risk associated with having both a de-
pressive disorder and an anxiety disorder on asthma
control and QoL. The researchers also noted that the
lack of an independent association between anxiety dis-
orders and asthma control may be due to the fact that
patients with anxiety disorder are more inclined to self-
monitor their symptoms, and are thus more likely than
depressed patients to detect asthma symptoms and seek
intervention.
Lavoie et al. [58] studied the association between clin-
ical measures of asthma morbidity and body mass index
(BMI), and found that patients with higher BMI scores
had worse asthma control and poorer QoL (i.e., higher
ACQ and lower AQLQ scores), independent of age, gen-
der, and asthma severity. However, BMI was not associ-
ated with asthma severity.
Discussion
This review is the first to summarize the literature
encompassing not only the clinical and economic bur-
den of asthma, but also the humanistic burden of
asthma in Canada. This systematic review confirms that
the burden associated with asthma is substantial, and
will undoubtedly become more pronounced as the
Table 10 Characteristics of humanistic burden studies included in the review







tion for OA in
Quebec
Examine association between clinical and
socioeconomic variables and psychological
and cost outcomes in patients with OA
Claimed compensation for OA at CSST, not
exposed to offending allergens causing OA
for ≥2 years
Workplace-associated respiratory symptoms
and positive results in specific inhalation test





Assess level of psychological distress and
range of disease-relevant emotional and be-
havioural coping styles in patients with se-
vere vs. moderate asthma
Patients aged 18–69 years recruited from 2
tertiary care outpatient asthma clinics
Standard ATS criteria; Severe asthma - re-
ceived adequate therapy and verified treat-
ment adherence, with patients meeting ATS









Assess associations between adult SES
(measured according to educational level)
and asthma morbidity, including asthma
control; asthma-related emergency health
service use; asthma self-efficacy, and asthma-
related QoL
Patients aged 18–75 years, recruited from
outpatient asthma clinic of Hôpital du Sacré-
Coeur de Montréal
Physician-diagnosed asthma - charted 20%
fall in FEV1 after methacholine challenge
and/or bronchodilator reversibility in FEV1 of
≥20% predicted; severity based on GINA
guidelines (mild intermittent, mild persistent,
moderate persistent, and severe persistent)





Evaluate validity of HUI-3, EQ-5D, SF-6D, and
AQL-5D to distinguish between different
levels of asthma control
Patients aged 19–49 years,no other
concurrent respiratory conditions
Self-reported, physician-diagnosed asthma





Examine effect of adding a LABA (salmeterol)
to fixed dose of oral prednisone and ICS
(fluticasone)
Patients aged 18–55 years, PEF of <80%
predicted before treatment, discharged from
ED
Clinically diagnosed acute asthma in ED; PEF
of <80% predicted before treatment






Evaluate utility of adding assessment of
airway inflammation to standard assessment
of impairment in subjects with OA; to
evaluate psychological and QoL impact of
OA









Evaluate relative impact of having a
depressive and/or anxiety disorder on
asthma control and QoL
Patients aged 18–75 years with primary
diagnosis of asthma
Physician-diagnosed asthma - chart evidence
of 20% fall in FEV1 after methacholine chal-
lenge and/or bronchodilator reversibility in
FEV1 20% predicted; severity classified ac-
cording to international GINA guidelines







Assess BMI in a Canadian sample of asthma
outpatients, and evaluate associations
between BMI and levels of asthma severity,
asthma control, and asthma-related QoL
Patients aged 18–75 years with primary
diagnosis of asthma, fluency in either English
or French
Physician diagnosed asthma - chart evidence
of 20% fall in FEV1 after methacholine chal-
lenge and/or bronchodilator reversibility in
FEV1 20% predicted; severity classified ac-
cording to GINA guidelines






Evaluate prevalence of psychiatric disorders
in adult asthma patients and associations
between psychiatric status, levels of asthma
control, and asthma-related QoL
Patients aged 18–75 years with primary
diagnosis of asthma, fluency in either English
or French
Physician diagnosed asthma - confirmed by
chart evidence of 20% fall in FEV1 after
methacholine challenge and/or bronchodila-
tor reversibility in FEV1 20% predicted; sever-
ity classified according to GINA guidelines
Mo et al. 2004 [59] 2000 - 2001 Cross-sectional study;
HUI used to measure
QoL
Measure HRQL of chronic disease and detect
associations between HUI system and
various chronic conditions























Table 10 Characteristics of humanistic burden studies included in the review (Continued)
FitzGerald et al.
2000 [60]
RCT - AQLQ adminis-
tered to assess QoL
Compare effectiveness of prednisone and
budesonide on relapse rate
Patients aged 15–70 years, recruited after
discharge from ED after acute asthma
exacerbation
Asthma exacerbation - progressive increase
in dyspnea and history of asthma as per ATS
criteria
Williams et al. 2010 [61] Baseline to
week 12
RCT AQLQ data from
first 12 weeks of the
GOAL study
Compare AQLQ data across 16 countries (17
languages)
Patients aged 12 to <80 years with ≥6-










Assess correlation between asthma-specific
QoL and levels of psychological distress and
psychiatric disorders in patients with OA
Patients who claimed compensation for OA
at CSST; no longer exposed to sensitizing
agents ≥2 years
OA - asthma caused and maintained by con-
ditions attributable to the occupational en-








Examine efficacy and safety of adding
regular formoterol at 2 different doses to
maintenance treatment with ICS in children
with asthma not optimally treated by ICS
alone
Patients aged 6–11 years with clinical
diagnosis of asthma as per ATS criteria for
≥6 months; FEV1 50-90% of predicted nor-
mal; documented post-bronchodilator revers-
ibility of ≥15%, ≥9% of predicted normal;
treatment with regular ICS for ≥3 months
before trial entry; asthma symptoms suffi-
cient to suggest additional therapy may be
needed; ability to use peak flow meter and
Turbuhaler®, able to answer questions from
PAQLQ; parent/guardian to complete daily
diary
Clinical diagnosis of asthma defined
according to ATS criteria; severe asthma
exacerbation defined as asthma symptoms
requiring oral corticosteroids or increase in
dose of ICS as judged by the investigator
ACQ=Asthma Control Questionnaire; AQLQ=Asthma Quality of Life Questionnaire; AQL-5D=Asthma Quality of Life-5D ; ATS=American Thoracic Society; BMI=body mass index; BUD=budesonide; CSST=Commission de
la Santé et de la Sécurité du Travail du Québec (Canadian Centre for Occupational Health and Safety); ED=emergency department; EQ-5D =EuroQoL 5-D ; FEV1=forced expiration volume in 1 second; GINA=Global
Initiative for Asthma; GOAL=Gaining Optimal Asthma ControL (study); GSCs=glucocorticosteroid; HRQoL = health-related quality of life; HUI=health utilities index; ICS=inhaled corticosteroid; LABA=long-acting
β-agonist; NR=not reported; OA=occupational asthma; PAQLQ=Pediatric Asthma Quality of Life Questionnaire; PEF=peak expiratory flow; PRED=prednisone; PRIME-MD=Primary Care Evaluation of Mental Disorders;
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http://www.biomedcentral.com/1471-2466/13/70asthma prevalence increases in Canada. The asthma bur-
den as it is known today can likely be decreased by the
development and implementation of innovative treat-
ment strategies in the management of this disease.
A considerable body of literature was included in this
systematic review (33 articles for the clinical and eco-
nomic burden and 14 for the humanistic burden).The
reviewed literature suggested that the healthcare re-
source utilization in asthma varied greatly in Canada by
age group and type of treatment used. The substantial
clinical burden was reflected by high rates of hospitaliza-
tions, ED and physician visits, and medication use.
Lower rates of ED visits and hospitalizations, as well as
reduced deaths, were observed among ICS users com-
pared with non-users (except among the elderly), but
these reductions were not as pronounced in patients
who had experienced recent asthma exacerbations.
We collected evidence on both the direct and indirect
components of the economic burden of asthma in Canada.
The overall burden varied based on whether studies re-
ported costs from the perspective of an individual patient
with asthma or costs at the population level. Reported esti-
mates for patient-level total direct costs, inflated to 2011
Canadian dollars, ranged from $99.33 per patient in a co-
hort of children aged 0–14 years in Ontario (May – Octo-
ber 1995) [33] to $646.95 per patient in a cohort of
children aged 0–9 years, also in Ontario (1994/1995) [24].
Reported estimates for population-level total direct costs,
inflated to 2011 Canadian dollars, ranged from $46,285,583
for patients aged 5–55 years in British Columbia (April
1996 – March 2000) [10] to $140,882,165 for patients
aged 0–9 years in Ontario (1994–1998) [24]. Few Canadian
studies reported a cost per episode of acute asthma.
Fourteen studies assessed the impact of asthma on the
QoL of patients; however, only 4 reported on QoL of chil-
dren with asthma, which represents a significant know-
ledge gap. For the most part, QoL assessments focused on
subgroups of the asthma population and studies had small
numbers of participants. Asthma was associated with de-
pression and/or anxiety in several studies.
As noted above, these research studies vary considerably
in terms of geographic region of study, characteristics of
patient populations, study methodologies, and definitions
of asthma used, which presents a significant challenge in
drawing definitive conclusions from our study. Further-
more, unique findings reported in single studies have yet
to be confirmed or refuted by subsequent research. Thus,
in our review, results are presented as reported, but no con-
sensus can be reached on the rates of resource utilization
among asthmatic patients, asthma-related costs, or the de-
gree of QoL impairment among individuals with asthma.
Our study suggests that there is a significant knowledge
gap in understanding the comprehensive burden of asthma
across Canada.Nevertheless, the high rates of healthcare resource
utilization observed among patients with asthma during
this review revealed only the tip of the iceberg. The eco-
nomic burden is noteworthy, with direct costs – particu-
larly those related to hospitalizations and physician/ED
visits – representing the highest proportion of asthma-
related costs. The indirect costs mainly due to time loss
from work, productivity loss, functional impairment and
caregiver time also add to this significant burden. Al-
though there is a paucity of research on the humanistic
burden of asthma in Canada, the few studies included in
this review indicate that QoL is unquestionably dimin-
ished in asthmatic patients and that there is a high
prevalence of psychological distress and psychiatric dis-
orders among patients with asthma. Notable knowledge
gaps on the humanistic burden of asthma are the lack of
QoL assessments in children and caregivers, as well as
quantifying the asthma-attributable burden in this pa-
tient population.
This systematic review provides a holistic overview of
the burden of asthma in Canada, detailing the direct and
indirect costs, the key drivers of healthcare resource
utilization, and the impact of asthma on patients’ quality
of life - information that cannot be inferred from clinical
measures. This information can be of value to payers,
policy makers and healthcare providers in making deci-
sions pertaining to the management and treatment of
asthma.
For example, knowing that depression is often associ-
ated with asthma and that its severity and asthma con-
trol are intertwined, it might be useful to have
psychologists/psychiatric healthcare professionals on the
disease management team from the time of asthma diag-
nosis. Also, findings that BMI levels and asthma control
and QoL are related, can lead to adding interventional
measures to the treatment strategy.
As far as treatment options go, the use of inhaled cor-
ticosteroids was noted in many of the reviewed articles
to be associated with lower rates of ED visits and hospi-
talizations; therefore recommending the appropriate use
of medications (low-dose SABA plus high-dose ICS)
should be emphasized.
More research in Canada is needed to add to the hol-
istic picture of the impact of this disorder on the lives of
patients, their families, and caregivers. Furthermore,
much remains to be learned about the optimal use of
the currently available treatments, how to combine them
for maximal benefit, and how to incorporate new drugs
in development into existing treatment regimens.
Limitations
All literature reviews are limited by the publication bias of
the articles that are available. We acknowledge the fact
that studies identifying a significant burden of asthma
Table 11 Clinical and economic burden search strategy
Medline (1996 to present)
1 Asthma[MeSH] OR Asthma [Title,abstract] 71642
2 hospitalisation[MeSH] OR cost of illness[MeSH] OR absenteeism OR ambulatory care/Economics[MeSH] OR drug costs[MeSH] OR
emergency medical services/Economics[EMTREE] OR healthcare costs[MeSH] OR nursing services/Economics[MeSH] OR physicians/
Economics[MeSH]
77559
3 (burden OR clinical impact OR hospitalisation OR utilization OR burden of illness OR cost$1 OR cost of illness OR utilization OR
nursing cost$1 OR physician cost$1 OR physician visit$1).TI,AB.
354392
4 1 AND (2 OR 3) 6208
5 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXT labrador OR
northwest territories OR nova scotia OR nunavut OR ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT
territory
462814
6 4 AND 5 AND LG=English AND HUMAN=YES 430
7 Publication Type=RANDOMIZED CONTROLLED TRIAL 223783
8 6 NOT 7 398
9 limit set 8 YEAR > 1999 324
EmBase (1992 to present)
10 Asthma[EMTREE] OR Asthma[Title,abstract] 100645
11 hospitalisation[EMTREE] OR cost of illness[EMTREE] OR cost[EMTREE] OR absenteeism[EMTREE] OR drug cost[EMTREE] OR healthcare
cost[EMTREE] OR nursing cost[EMTREE]
348772
12 (burden OR clinical impact OR hospitalisation OR utilization OR burden of illness OR cost$1 OR cost of illness OR utilization OR
nursing cost$1 OR physician cost$1 OR physician visit$1)[Title,abstract]
381230
13 10 AND (11 OR 12) 10735
14 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXT labrador OR
northwest territories OR nova scotia OR nunavut OR ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT
territory
462680
15 13 AND 14 AND LG=English AND HUMAN=YES 654
16 Randomized Controlled Trial[EMTREE] OR Randomized Controlled Trial Topic[EMTREE] 249284
17 15 NOT 16 596
18 limit set 17 YEAR > 1999 515
EMCare
19 Asthma[EMTREE] OR Asthma[Title,abstract] 28554
20 hospitalisation[EMTREE] OR cost of illness[EMTREE] OR cost[EMTREE] OR absenteeism[EMTREE] OR drug cost[EMTREE] OR healthcare
cost[EMTREE] OR nursing cost[EMTREE]
152470
21 (burden OR clinical impact OR hospitalisation OR utilization OR burden of illness OR cost$1 OR cost of illness OR utilization OR
nursing cost$1 OR physician cost$1 ORphysician visit$1)[Title,abstract]
156234
22 19 AND (20 OR 21) 4228
23 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXT labrador OR northwest
territories OR nova scotia OR nunavut OR ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT territory
174145
24 22 AND 23 AND LG=EN 312
25 Randomized Controlled Trial[EMTREE] OR Randomized Controlled Trial[EMTREE] 82273
26 24 NOT 25 278
27 limit set 26 YEAR > 1999 222
Medline, EmBase and EMCare combined
28 combined sets 9, 18, 27 1061
29 dropped duplicates from 28 486
30 unique records from 28 575
31 split set 30 320 Medline
32 split set 30 234 EmBase
33 split set 30 21 EmCare
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Table 12 Humanistic burden search strategy
Medline
1 Asthma[MeSH] OR Asthma[Title,Abstract] 71642
2 Sickness impact profile[MeSH] OR quality of life[MeSH] OR patient satisfaction[MeSH] 121478
3 (quality of life OR QoL OR patient reported outcome$1 OR patient satisfaction OR emotional satisfaction OR patient dissatisfaction
OR patient response OR gratification OR treatment satisfaction OR disability rate$1 OR health related quality of life OR HRQoL OR
utilities) [Title,Abstract]
119368
4 1 AND (2 OR 3) 3035
5 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXTlabrador OR northwest
territories OR nova scotia OR nunavut OR ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT territory
462814
6 4 AND 5 AND LG=English AND HUMAN=YES 172
7 limit set 6 YEAR > 1999 141
EmBase
8 Asthma[EMTREE] OR Asthma[Title,Abstract] 100645
9 Sickness impact profile[EMTREE] OR quality of life[EMTREE] OR patient satisfaction[EMTREE] 199618
10 (quality of life OR QoL OR patient reported outcome$1 OR patient satisfaction OR emotional satisfaction OR patient dissatisfaction
OR patient response OR gratification OR treatment satisfaction OR disability rate$1 OR health related quality of life OR HRQoL OR
utilities) [Title,Abstract]
124979
11 8 AND (9 OR 10) 5651
12 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXT labrador OR
northwest territories OR nova scotia OR nunavut OR Ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT
territory
462680
13 11 AND 12 AND LG=English AND HUMAN=YES 306
14 limit set 13 YEAR > 1999 267
EMCare
15 Asthma[EMTREE] OR Asthma[Title,Abstract] 28554
16 Sickness impact profile[EMTREE] OR quality of life[EMTREE] OR patient satisfaction[EMTREE] 94595
17 (quality of life OR QoL OR patient reported outcome$1 OR patient satisfaction OR emotional satisfaction OR patient dissatisfaction
OR patient response OR gratification OR treatment satisfaction OR disability rate$1 OR health related quality of life OR HRQoL OR
utilities) [Title,Abstract]
48206
18 15 AND (16 OR 17) 2178
19 canada OR canadian OR alberta OR british columbia OR manitoba OR new brunswick OR newfoundland NEXT labrador OR
northwest territories OR nova scotia OR nunavut OR Ontario OR prince edward island OR quebec OR saskatchewan OR yukon NEXT
territory
174145
20 18 AND 19 AND LG=English 137
21 limit set 20 YEAR > 1999 111
Medline, EmBase and EMCare combined
22 combined sets 7, 14, 21 519
23 dropped duplicates from 22 207
24 unique records from 22 312
25 split set 24 141
Medline
26 split set 24 158
EmBase
27 split set 24 13 EMCare
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den. The articles in this review are limited to the English
language, and publication constraints were placed on arti-
cles identified by the search with studies limited to those
published since 2000. Spatial restrictions were also ap-
plied, limiting studies to Canada. Studies employed avariety of defining criteria for asthma (from patient self-
report to ICD-codes, from physician-recorded diagnosis
to discharge diagnosis combined with medication use),
and these definitions were not reconciled in this review.
This may have led to underreporting or overreporting of
certain outcomes. Results were analyzed as reported, but
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high heterogeneity of methodological approaches.
In spite of these limitations, this review was systematic
in nature and summarizes all available and relevant data
published since 2000, thus providing a better under-
standing of the literature with respect to the clinical,
economic, and humanistic burden of asthma.Conclusions
The information contained within this study provides a
comprehensive overview of the burden of asthma in
Canada. Moreover, our study identifies several key
knowledge gaps in understanding this area. As new ther-
apies for asthma become available, health technology as-
sessments will become increasingly important not only
as it pertain to amendments to clinical practice guide-
lines but also with regard to formulating reimbursement
decisions. Our study summarizes information that can
prove important for physicians, healthcare authorities,
and government officials involved in the treatment selec-
tion and development of disease management guidelines
for asthma.Appendix
The Appendix tables present the literature search strat-
egies used to retrieve articles reporting on the clinical
and economic burden (Table 11) and humanistic burden
(Table 12) of asthma. The strategies were applied to the
Medline. EmBase and EMCare databases.
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